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Background: Di(2-ethylhexyl) phthalate (DEHP) exposure reduces embryo implantations, increases embryonic loss,
and decreases fetal body weights. However, whether it is associated with the alteration of luteal function remains
unknown. Thus, our aim in this study was to explore the effect and mechanism of DEHP on luteal function in
pregnant mice in vivo.
Methods: Mice were administered DEHP by gavage at 125, 250, 500 mg/kg/day from gestational days (GD) 1 to 9
or 13. Levels of serum progesterone and estradiol were measured by radioimmunoassay. The numbers and sizes of
corpora lutea were calculated by ovarian histomorphology. Steroidogenic enzymes were assessed by qRT-PCR.
CD31 protein was detected by immunocytochemistry, and prostaglandin F2alpha (PGF2alpha) levels were evaluated
by enzyme immunoassay.
Results: Treatment with DEHP significantly inhibited progesterone secretion in pregnant mice in a dose-dependent
manner but did not inhibit estradiol production on GD 9 and 13. Treatment also showed concomitant decreases in
transcript levels for key steroidogenic enzymes (CYP11A, 3β-HSD, and StAR) on GD 13. Furthermore, DEHP administration
significantly reduced the numbers and sizes of corpora lutea on GD 13. No significant changes in the ratio of ovary weight
vs. body weight were observed between the control group and treated animals on GD 9 and 13. In addition, treatment
with DEHP significantly inhibited CD31 expression of corpora lutea, whereas plasma PGF2alpha levels in DEHP treatment
groups were significantly higher compared with the control groups on GD 9 and 13.
Conclusions: The results show DEHP significantly inhibits luteal function of pregnant mice in vivo, with a mechanism that
seems to involve the down-regulation of progesterone and steroidogenic enzymes message RNA, the decrease in CD31
expression, and the increase in PGF2alpha secretion.
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Di(2-ethylhexyl) phthalate (DEHP) is used as a
plasticizer in flexible polyvinyl chloride (PVC) products,
including food and beverage packaging, cosmetics, medical
devices, construction products and children’s toys [1]. Cur-
rently, DEHP is the most widespread phthalate, accounting
for approximately 50% of the market for PVC plasticizers
in the European Union [2,3]. DEHP loosely binds to plastic
materials, so it easily leaches out of these products and* Correspondence: kuanghaibin@ncu.edu.cn
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unless otherwise stated.enters into the environment over time and with product
use. The Agency for Toxic Substances and Disease
Registry estimates that the maximum daily exposure to
DEHP for the general population is approximately 2 mg/day
[4]. However, occupational, medical and dust exposures
can lead to much higher levels of exposure. For example,
exposure to DEHP from blood transfusions can be
as high as 250–300 mg, equivalent to a dose of
3.5-4.3 mg/kg for an adult weighing 70 kg, and the
levels of DEHP in household dust can reach as high
as 400–700 mg/kg [4,5].
Recently, emerging evidence has suggested that expos-
ure to DEHP has potential hazardous effects on animalis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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notoxicity, neurotoxicity and especially reproductive tox-
icity [4]. In males, studies showed that exposure to DEHP
increased germ cell apoptosis, disrupted spermatogenesis
and inhibited steroidogenesis of Leydig cells [6-9]. Women
are exposed to DEHP more frequently than men due to its
widespread use in nail polish, shampoos and cosmetics
[10]. Studies in vivo demonstrated that DEHP exposure
prolonged estrous cycles, decreased serum estradiol levels
and inhibited ovulations in adult rats. In vitro, mono-
(2-ethylhexyl) phthalate (MEHP, the active metabolite of
DEHP) decreases granulosa cell aromatase message RNA
and protein levels [4,11]. Chronic and long-term occupa-
tional exposure to phthalates has been associated with
endometriosis, lower rates of pregnancy, high miscarriage
rates and pregnancy complications such as anemia and
hypertensive disorders in women [12,13]. In female la-
boratory rats, DEHP reduces endometrial receptivity and
embryo implantations, increases embryonic loss, and de-
creases fetal body weights [4,14,15]. However, whether it is
associated with the alteration of luteal function remains
unknown. Thus, our aim in this study was to explore the
effect and mechanism of DEHP on early- and mid-luteal
function in pregnant mice. Our results indicated that daily
exposure to DEHP inhibits luteal function in pregnant
mice through a mechanism that seems to involve proges-
terone and steroidogenic enzymes down-regulation, a de-




Adult female CD-1 mice (25–30 g) were contained in a
consistent photoperiod (14 h light: 10 h dark cycle) and
allowed free access to food and water. The experimental
protocols were approved by the Institutional Animal
Care and Use Committee of Nanchang University
(Permit Number: NJ20130616). The ethical approval date
was June 16, 2013 and the study was initiated July, 2013.
Adult virgin female mice were mated with fertile males
of the same strain to induce pregnancy. The morning
following the identification of a vaginal plug was desig-
nated as day 1 (D1) of gestation. The pregnant animals
were divided into 4 groups as follows (n = 20/group): (1)
control group, (2) 125 mg/kg/day DEHP group, (3)
250 mg/kg/day DEHP group and (4) 500 mg/kg/day
DEHP group. From D1 until the conclusion of the
experiment, pregnant female mice were weighed and
administered DEHP (Guo Lei Chemicals, China) dissolved
in sesame oil (Sigma, USA) at various concentrations
(125, 250 and 500 mg/kg/day) by gavage (0.1 ml/10 g
body weight). The control group mice were given the
same volume of sesame oil. Treated mice were sacrificed
for ovary collection between 15:00 and 16:00 ongestational day (GD) 9 and 13 by cervical dislocation
(10 mice for each group on GD9 and GD13), respectively.
Ovaries from these mice were frozen in liquid nitrogen for
further analysis.
Ovarian histomorphology
Tissues were fixed in Bouin’s solution for 12 h, de-
hydrated in ethanol, and embedded in paraffin. Tissue
sections were cut at 5 μm and stained with hematoxylin
and eosin for morphological evaluation. The numbers of
corpora lutea were calculated by counting the numbers
in both ovaries and generating an average number per
individual. Images were captured in six ovary sections
per animal using digital camera head DS-Fi1 (Nikon,
Japan), and the sizes of the corpora lutea were measured
using ImageJ (v. 1.45 s, NIH).
Immunohistochemistry
Tissue sections (5 μm) were deparaffinized in xylene and
hydrated in graded ethanol solutions followed by water.
Sections were placed in 0.01 M citric acid (pH= 6) and
microwaved for 15 min to expose the antigens. Endogenous
peroxidase activity was blocked by incubating the sections
in 3% hydrogen peroxide in PBS for 10 min. Nonspecific
binding was blocked in 5% BSA in PBS for 60 min. Then,
the sections were incubated with rabbit anti-CD31 (1:150,
Santa Cruz, USA) overnight at 4°C. After washing in PBS,
the sections were incubated with a secondary antibody for
45 min at 37°C. The primary antibody was detected with
fresh diaminobenzidine solution, in conjunction with
counter-staining using Harris’ hematoxylin. In some sec-
tions, the primary antibodies were replaced with rabbit
preimmune IgG as a negative control.
Quantitative PCR
Total RNA was extracted from ovary tissues with
RNAiso Plus solution (TaKaRa, China) according to the
manufacturer’s protocol. RNA samples were reverse-
transcribed into single-stranded cDNA in a 25 μl reac-
tion mixture (TaKaRa, China). Real-time PCR was then
performed in a 20 μl reaction volume containing 10 μl
of 2x Brilliant SYBR Green Mix (TaKaRa, China), 2 μl of
template cDNA, 0.5 μM primers, and 300 nM reference
dye using the ABI thermal cycler 7500. The thermal cyc-
ling conditions were 95°C for 30 sec, followed by 40 cy-
cles at 94°C for 5 sec and 60°C for 34 sec. Melting curve
analysis and agarose gel electrophoresis were conducted
following the quantitative PCR assays to monitor PCR
product purity. The results were analyzed using ABI
Prism 7500 software (Applied Biosystems, USA), and18S
identified to be stable in the DEHP-treated experiment
was used as an internal control. The following primers
were used: 18S (ACCESSION:NR_003278): sense, 5′-AAT
CAG GGT TCG ATT CCG GA–3′; antisense, 5′-CCA
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NM_011485): sense, 5′-CGC AGA GGT TCC ACC TGT
GT-3′; antisense, 5′-TCC GGC ATC TCC CCA AA-3.
CYP11A(ACCESSION:NM_019779): sense, 5′-CCG GAG
CGG TTC CTT GT-3′; antisense, 5′-CCA ATG GGC
CTC TGA TAA TAC TG-3′. 3β-HSD(ACCESSION:
NM_013821): sense, 5′-GGA GGA AGC CAA GCA
GAA AA-3′; antisense, 5′-CCC TGT GCT GCT CCA
CTA GTG-3′.
Enzyme immunoassay (EIA)
Concentrations of PGF2alpha were measured in plasma
using a commercially available EIA kit (Cayman Chemical)
according to the manufacturer’s instructions. The intra-
and inter-assay coefficients of variation did not exceed
7.1% and 8.2%.
Hormone measurements
The plasma concentrations of estradiol (E2) and proges-
terone (P4) were measured using specific RIA kits (Jiuding
Medicine Biotechnology Co, China). Samples were de-
tected in duplicate. The intra- and inter-assay coeffi-
cients of variation using these kits did not exceed 10%.
The cross-reactivities with other peptides and steroid
hormones in these kits did not exceed 4%. The detec-
tion limits of the E2 and P4 kits are 1 pg/ml and
0.25 ng/ml, respectively.Figure 1 Effect of DEHP exposure on serum estradiol and progesterone
estradiol levels on day 13 of pregnancy. (C) Serum progesterone levels on day
The results are shown as the means +/− SD of 10 animals. Groups with differe
by LSD multiple range test).Statistical analysis
The data are presented as the means +/− SD. The results
were analyzed by using one-way ANOVA followed by
LSD’s post-hoc test. A value of P < 0.05 was considered
to be statistically significant. All statistical analyses were
performed using the Statistical Package for the Social
Sciences (SPSS, Chicago, IL) 13.0.
Results
DEHP administration inhibits luteal function in
pregnant mice
As shown in Figure 1A and B, treatment with DEHP did
not affect estradiol levels, whereas it induced a signifi-
cant decrease in plasma progesterone levels in a dose-
dependent manner compared with the control group on
GD 9 and 13 (all P < 0.01, Figure 1C and D). In addition,
administration of DEHP did not affect the ratios of ovary
weight to body weight on GD 9 and 13 (Figure 2A and
B). No statistically significant difference related to the
numbers of corpora lutea was observed between the
control group and treated animals at any dose level on
GD 9 (Figures 2C and 3A). However, the administration
of various doses of DEHP significantly reduced the
numbers of corpora lutea on GD13 (all P < 0.01,
Figures 2D and 3B) and the sizes of corpora lutea on
GD9 and 13 (P < 0.05 or 0.01, Figures 2E-F and 3B),
compared to the control group.levels. (A) Serum estradiol levels on day 9 of pregnancy. (B) Serum
9 of pregnancy. (D) Serum progesterone levels on day 13 of pregnancy.
nt superscript letters are significantly different (P < 0.05, ANOVA followed
Figure 2 Effect of DEHP exposure on the ovarian weights, numbers and sizes of corpora lutea. (A) Ratio of ovary/body weight on day 9
of pregnancy. (B) Ratio of ovary/body weight on day 13 of pregnancy. (C) Numbers of corpora lutea on day 9 of pregnancy. (D) Numbers of
corpora lutea on day 13 of pregnancy. (E) Sizes of corpora lutea on day 9 of pregnancy. (F) Sizes of corpora lutea on day 13 of pregnancy. The
results are shown as the means +/− SD of 10 animals. Groups with different superscript letters are significantly different (P < 0.05, ANOVA
followed by LSD multiple range test).
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enzymes in pregnant mice
To investigate the underlying mechanism of progester-
one decrease from DEHP treatment, we detected the
mRNA levels of three key steroidogenic enzymes:
(1) steroidogenic acute regulatory protein (StAR)
(Figure 4A,B), (2) cytochrome P45011A (CYP11A)
(Figure 4C,D), and (3) 3-hydroxysteroid dehydrogenase
(3β-HSD) (Figure 4E,F), by real-time PCR. Compared
to the control group, administration of different doses
of DEHP inhibited levels of CYP11A and 3β-HSD
mRNA on GD 9 and 13 (Figure 4C-F). However, on
gestational day 9, StAR mRNA levels were similar in
the control and DEHP-treated animals (Figure 4A).
Only the 125 mg DEHP/kg/day dose group showed sig-
nificantly increased levels of StAR mRNA compared with
the control group(P < 0.01, Figure 4A). In addition, treat-
ment with DEHP significantly attenuated StAR mRNA
levels compared to control on GD 13 (P < 0.05 or 0.01,
Figure 4B).Effect of DEHP exposure on luteal vascularization and
PGF2alpha levels in pregnant mice
As shown in Figure 5A and B, treatment with DEHP sig-
nificantly inhibited vascularization of corpora lutea com-
pared with the control group on GD 9 and 13 (Additional
file 1), as evidenced through CD31 immunostaining. How-
ever, on gestational day 9, the 250 mg and 500 DEHP/kg/
day dose groups showed significantly enhanced plasma
PGF2alpha levels compared with the control group (P <
0.05, 0.01, Figure 6A). Moreover, plasma PGF2alpha levels
in all DEHP treatment groups were significantly greater
compared to the control group’s concentrations on GD 13
(P < 0.05 or 0.01, Figure 6B).
Discussion
The present study is, to the best of our group’s know-
ledge, the first to examine the effects of DEHP on luteal
function during mouse pregnancy in vivo. The results
indicate that treatment with DEHP significantly inhibited
progesterone secretion but did not inhibit estradiol
Figure 3 Ovarian histomorphology detected by H&E staining. (A) Representative images of ovary on day 9 of pregnancy. (B) Representative
images of ovaries on day 13 of pregnancy. Squared areas at the top (×40) are presented at higher magnification (×200) at the bottom. CL, corpus
luteum; F, follicle.
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levels for key steroidogenic enzymes (CYP11A, 3β-HSD,
and StAR). Furthermore, DEHP administration signifi-
cantly reduced the numbers and sizes of corpora lutea
on gestational day 13 but did not reduce the ratios of
ovary weights vs. body weighs on gestational days 9 and
13. In addition, administration of DEHP to pregnant
mice was associated with the decrease in luteal CD31
expression and increase in serum PGF2alpha secretion.
These findings suggest that increased miscarriages and
decreased pregnancy rates in gestational mice exposed to
DEHP are possibly mediated, at least in part, via suppres-
sion of ovary luteal function, a decrease in luteal CD31
expression and an increase in serum PGF2alpha secretion.
Progesterone plays a vital role in the maintenance of
pregnancy and development of the fetus, and adequate
levels of progesterone are essential for normal uterine
decidualization and establishment of early pregnancy
[16,17]. In the present study, we first explored the effects
of DEHP on ovary luteal function during mouse preg-
nancy in vivo. The results showed that DEHP treatment
significantly inhibited progesterone release in a dose-
dependent manner but did not inhibit estradiol produc-
tion. This is consistent with Francesco Parillo’s result
[18], in which DEHP exposure also decreased plasma
progesterone levels and corpora lutea production inearly, mid, and late stages of rabbit pseudopregnancy.
Furthermore, Federica Romani showed that DEHP and
other phthalates negatively influence luteal steroido-
genesis by reducing both basal and hCG-stimulated-
progesterone release in highly purified human luteal
cells [19]. In addition, Li et al. indicated that DEHP re-
duces progesterone levels and induces apoptosis of
ovarian granulosa cells in adult female ICR mice [20].
However, Maria A. Herreros’s research [21] indicated
that doses of 25 and 50 mg/kg of DEHP reduced the
sizes of corpora lutea in sheep, but plasma progester-
one levels in DEHP-treated ewes were unusually higher
than in the control group. In addition, DEHP-exposed
ewes had significantly higher plasma progesterone con-
centration from Day 2 of the luteal phase [22]. One
possible explanation of this unexpected finding would
be the fact that plasma progesterone concentrations in
DEHP-treated sheep were elevated not as a result of an
increased secretion but due to diminished clearance of
progesterone. In fact, some studies showed that plasma
progesterone levels were affected more by its metabolic
clearance than by the level of secretion from corpora
lutea [21]. The confirmation of this postulated mechan-
ism requires further investigation.
Our data indicated that treatment with DEHP inhibited
levels of CYP11A and 3β-HSD mRNA on gestational days
Figure 4 Effect of DEHP exposure on the expression of different steroidogenic enzymes mRNA. (A, B) StAR mRNA levels in the ovary on
day 9 (A) and 13 (B) of pregnancy. (C, D) CYP11A mRNA levels in the ovary on day 9 (C) and 13 (D) of pregnancy. (E, F) 3β-HSD mRNA levels in
the ovary on day 9 (E) and 13 (F) of pregnancy. mRNAs levels were quantified using quantitative PCR and were normalized to 18S. The data are
represented as the means +/− SD of 10 animals. Groups with different superscript letters are significantly different (P < 0.05, ANOVA followed by
LSD multiple range test).
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tional day 13, while StAR mRNA levels were similar in
control and DEHP-treated animals on gestational day 9. In
vitro-cultured luteal cells, DEHP treatment diminished
progesterone production and 3β-HSD protein levels in
early and mid corpora lutea. However, in vivo DEHPFigure 6 Effect of DEHP exposure on prostaglandin F2alpha levels on
PGF2alpha on day 9 (A) and 13 (B) of pregnancy. The results are shown as
letters are significantly different (P < 0.05, ANOVA followed by LSD multipletreatment did not affect 3β-HSD protein in pseudo-
pregnant rabbits [18]. In cultured murine leydig tumor cell
line MLTC-1, CYP11A, CYP17, and 3β-HSD showed in-
creased expression following exposure to DEHP, but some
insignificant inhibitory effects appeared in the 10 μmol/L
treatment group compared to the controls [7,23]. Theseday 9 and 13 of pregnancy. (A, B) Plasma concentrations of
the means +/− SD of 10 animals. Groups with different superscript
range test).
Figure 5 Expression levels of CD31 protein detected by immunohistochemistry. (A, B) Representative images of ovaries on day 9 (A) and
13 (B) of pregnancy. Squared areas at the top (×40) are presented at higher magnification (×200) at the bottom. Inset is negative control.
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of steroidogenesis-related enzymes and progesterone pro-
duction are species dependent, environment dependent
and dose dependent.
PGF2alpha is recognized as having a decisive role in
the functional regression of the corpus luteum [24]. Our
results showed that treatment with DEHP significantly
enhanced plasma PGF2alpha levels compared with the
control group, suggesting that DEHP inhibited the luteal
synthesis of progesterone by PGF2alpha-induced luteoly-
sis in pregnant mice. In addition, Wang X et al. also in-
dicated that DEHP stimulated secretion of PGF2alpha
and inhibited secretion of PGE2 in cultured luteal cells
from cows on days 8–12 of the estrous cycle [25]. Fur-
thermore, our results indicated that DEHP treatment
significantly induced the up-regulation of COX2 protein
compared to control group (Additional files 2 and 3),
which is key enzyme and catalyzes the rate-limiting step
in prostaglandin biosynthesis. However, Romani F et al.
demonstrated that PGF2alpha release and PGE2 release
were both reduced after DEHP incubation in human lu-
teal cells [19]. The data above suggest that ovarian luteo-
lysis may be regulated by PGF2alpha release or by the
dysregulation between luteotrophic and luteolytic factors,
such as the ratios of PGF2alpha/PGE2. PGF2alpha de-
creases progesterone synthesis by a number of intracellular
mechanisms, including downregulation of receptors for
luteotropic hormones and decreased activity of thesteroidogenic enzymes required for the biosynthesis of
progesterone and the induction of cell death [24]. The
precise mechanism of this effect requires further study.
Vascularization is essential for the development of a
functional corpus luteum.
Our study has shown that treatment with DEHP signifi-
cantly inhibited CD31 protein expression in the corpora
lutea. Ban JB et al. showed that MEHP could induce apop-
tosis of human umbilical vein endothelial cells through a
reactive oxygen species-mediated mitochondria-dependent
pathway [26]. In addition, Federica Romani indicated that
levels of VEGF protein in human luteal cells had a statisti-
cally significant decrease after incubation with DEHP [19].
Moreover, DEHP treatment negatively affects the develop-
ment of retinal vessels in newborn rats [27]. These data
suggest that DEHP negatively influences corpus luteum
function by inhibiting luteal angiogenesis in pregnant mice.Conclusions
Exposure to DEHP significantly inhibited the luteal func-
tion of pregnant mice, with a mechanism that seems to
involve the down-regulation of progesterone and ste-
roidogenic enzymes, a decrease in CD31 expression and
an increase in PGF2alpha secretion. Further studies are
needed to identify the causes of these aberrations and
their consequences to fertility. The systemic effect of
DEHP treatment remains unknown in pregnant mice.
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Additional file 1: Relative expression levels of CD31 protein
detected by immunohistochemistry. (A, B) Relative expression levels
of CD31 protein in the ovaries on day 9 (A) and 13 (B) of pregnancy.
Groups with different superscript letters are significantly different
(P < 0.05, ANOVA followed by LSD multiple range test).
Additional file 2: The expression of COX2 protein detected by
immunohistochemistry. (A, B) Representative images of ovaries on day
9 (A) and 13 (B) of pregnancy. Squared areas at the top (×100) are
presented at higher magnification (×200) at the bottom. Inset is negative
control. CL, corpus luteum.
Additional file 3: Relative expression levels of COX2 protein
detected by immunohistochemistry. (A, B) Relative expression levels
of COX2 protein in the ovaries on day 9 (A) and 13 (B) of pregnancy.
Groups with different superscript letters are significantly different
(P < 0.05, ANOVA followed by LSD multiple range test).
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PVC: Polyvinyl chloride; qRT-PCR: Quantitative reverse transcription PCR.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MJG, LDL, TZ and HBK conceived and designed the study. MJG, LDL and TZ
carried out all the experiments. BY and YL performed statistical analysis. MJG,
LDL, LZ and ML drafted the paper and amended the paper. All authors read
and approved the final manuscript.
Acknowledgments
This work was supported by the National Natural Science Foundation of
China (31260248, 81270668, 30960118 and 81460226) and The 555 project of
Jiangxi Province Gan Po Excellence and Academic and Technical Leader
Foundation of Jiangxi province and Jiangxi Post-graduate Innovation Project
(YC2014-S077). We also acknowledge Valerie L. and Peter D. at the American
Journal Experts (AJE), for their editing and polish to improve the manuscript.
Author details
1Department of Physiology, School of Medicine, Nanchang University,
Nanchang, Jiangxi, China. 2Department of Obstetrics and Gynecology,
Hospital of Jixi Province People, Nanchang, Jiangxi, China.
Received: 5 November 2014 Accepted: 23 February 2015
References
1. Kamrin MA. Phthalate risks, phthalate regulation, and public health: a
review. J Toxicol Environ Health B Crit Rev. 2009;12:157–74.
2. Andrade AJ, Grande SW, Talsness CE, Gericke C, Grote K, Golombiewski A,
et al. A dose response study following in utero and lactational exposure to
di-(2-ethylhexyl) phthalate (DEHP): reproductive effects on adult male
offspring rats. Toxicology. 2006;228:85–97.
3. Shin IS, Lee MY, Cho ES, Choi EY, Son HY, Lee KY. Effects of maternal
exposure to di(2-ethylhexyl)phthalate (DEHP) during pregnancy on
susceptibility to neonatal asthma. Toxicol Appl Pharmacol. 2014;274:402–7.
4. Lovekamp-Swan T, Davis BJ. Mechanisms of phthalate ester toxicity in the
female reproductive system. Environ Health Perspect. 2003;111:139–45.
5. Becker K, Seiwert M, Angerer J, Heger W, Koch HM, Nagorka R, et al. DEHP
metabolites in urine of children and DEHP in house dust. Int J Hyg Environ
Health. 2004;207:409–17.
6. Vo TT, Jung EM, Dang VH, Yoo YM, Choi KC, Yu FH, et al. Di-(2 ethylhexyl)
phthalate and flutamide alter gene expression in the testis of immature
male rats. Reprod Biol Endocrinol. 2009;7:104.
7. Chen X, Liu YN, Zhou QH, Leng L, Chang Y, Tang NJ. Effects of low
concentrations of di-(2-ethylhexyl) and mono-(2-ethylhexyl) phthalate onsteroidogenesis pathways and apoptosis in the murine leydig tumor cell
line MLTC-1. Biomed Environ Sci. 2013;26:986–9.
8. Doyle TJ, Bowman JL, Windell VL, McLean DJ, Kim KH. Transgenerational
effects of di-(2-ethylhexyl) phthalate on testicular germ cell associations and
spermatogonial stem cells in mice. Biol Reprod. 2013;88:112.
9. Huang LP, Lee CC, Hsu PC, Shih TS. The association between semen quality
in workers and the concentration of di(2-ethylhexyl) phthalate in polyvinyl
chloride pellet plant air. Fertil Steril. 2011;96:90–4.
10. Hannon PR, Peretz J, Flaws JA. Daily exposure to Di(2-ethylhexyl) phthalate
alters estrous cyclicity and accelerates primordial follicle recruitment
potentially via dysregulation of the phosphatidylinositol 3-kinase signaling
pathway in adult mice. Biol Reprod. 2014;90:136.
11. Davis BJ, Maronpot RR, Heindel JJ. Di-(2-ethylhexyl) phthalate suppresses
estradiol and ovulation in cycling rats. Toxicol Appl Pharmacol.
1994;128:216–23.
12. Heudorf U, Mersch-Sundermann V, Angerer J. Phthalates: toxicology and
exposure. Int J Hyg Environ Health. 2007;210:623–34.
13. Kim SH, Chun S, Jang JY, Chae HD, Kim CH, Kang BM. Increased plasma
levels of phthalate esters in women with advanced-stage endometriosis: a
prospective case–control study. Fertil Steril. 2011;95:357–9.
14. Li R, Yu C, Gao R, Liu X, Lu J, Zhao L, et al. Effects of DEHP on endometrial
receptivity and embryo implantation in pregnant mice. J Hazard Mater.
2012;241–242:231–40.
15. Kaul AF, Souney PF, Osathanondh R. A review of possible toxicity of di-2-
ethylhexylphthalate (DEHP) in plastic intravenous containers: effects on
reproduction. Drug Intell Clin Pharm. 1982;16:689–92.
16. Ema M, Miyawaki E. Effects of monobutyl phthalate on reproductive
function in pregnant and pseudopregnant rats. Reprod Toxicol.
2001;15:261–7.
17. Yochim JM, De Feo VJ. Hormonal control of the onset, magnitude and
duration of uterine sensitivity in the rat by steroid hormones of the ovary.
Endocrinology. 1963;72:317–26.
18. Parillo F, Maranesi M, Brecchia G, Gobbetti A, Boiti C, Zerani M. In vivo
chronic and in vitro acute effects of di(2-ethylhexyl) phthalate on
pseudopregnant rabbit corpora lutea: possible involvement of peroxisome
proliferator-activated receptor gamma. Biol Reprod. 2014;90:41.
19. Romani F, Tropea A, Scarinci E, Federico A, Dello Russo C, Lisi L, et al.
Endocrine disruptors and human reproductive failure: the in vitro effect of
phthalates on human luteal cells. Fertil Steril. 2014;102:831–7.
20. Li N, Liu T, Zhou L, He J, Ye L. Di-(2-ethylhcxyl) phthalate reduces progesterone
levels and induces apoptosis of ovarian granulosa cell in adult female ICR mice.
Environ Toxicol Pharmacol. 2012;34:869–75.
21. Herreros MA, Gonzalez-Bulnes A, Inigo-Nunez S, Contreras-Solis I, Ros JM,
Encinas T. Toxicokinetics of di(2-ethylhexyl) phthalate (DEHP) and its effects
on luteal function in sheep. Reprod Biol. 2013;13:66–74.
22. Herreros MA, Encinas T, Torres-Rovira L, Garcia-Fernandez RA, Flores JM,
Ros JM, et al. Exposure to the endocrine disruptor di(2-ethylhexyl)phthalate
affects female reproductive features by altering pulsatile LH secretion.
Environ Toxicol Pharmacol. 2013;36:1141–9.
23. Stone D, Hechter O. Studies on ACTH action in perfused bovine adrenals:
the site of action of ACTH in corticosteroidogenesis. Arch Biochem Biophys.
1954;51:457–69.
24. Stouffer RL, Bishop CV, Bogan RL, Xu F, Hennebold JD. Endocrine and local
control of the primate corpus luteum. Reprod Biol. 2013;13:259–71.
25. Wang X, Shang L, Wang J, Wu N, Wang S. Effect of phthalate esters on the
secretion of prostaglandins (F2alpha and E2) and oxytocin in cultured
bovine ovarian and endometrial cells. Domest Anim Endocrinol.
2010;39:131–6.
26. Ban JB, Fan XW, Huang Q, Li BF, Chen C, Zhang HC, et al. Mono-(2-ethylhexyl)
phthalate induces injury in human umbilical vein endothelial cells. PLoS One.
2014;9:e97607.
27. Zei D, Pascarella A, Barrese C, Pantalone S, Stefanini S. DEHP effects on
retinal vessels in newborn rats: a qualitative and quantitative analysis.
Histochem Cell Biol. 2009;132:567–75.
